Invention:
This technology is an intranasal and/or inhaled therapeutic that consists of a bacterial extract. Initial studies have shown that it protects against characteristic asthma phenotypes such as airway hypperresponsiveness, bronchoalveolar lavage eosinophillia, and increased expression of type-2 cytokines in the lung. The therapy can protect against various allergens that are known to cause asthma.
Background:
Asthma is considered a lifelong disease and can lower quality of life. It is estimated that roughly 25 million people have asthma, with nearly half of these people having an asthma attack annually. Costs associated with asthma have been estimated around $56 billion annually. This technology has the potential to not only treat, but prevent asthma if taken proactively.
